Cargando…

Outcome of myeloma patients with COVID-19 on active lenalidomide-based therapy: Does lenalidomide protect from severe COVID-19?

Detalles Bibliográficos
Autores principales:	Tailor, Imran K., Alshehry, Nawal F., Zaidi, Syed Z., Marei, Mohammed A., Motabi, Ibraheem H., Alfayez, Mansour, Altaf, Syed Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. 2020
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492149/ https://www.ncbi.nlm.nih.gov/pubmed/36634278 http://dx.doi.org/10.1016/j.hemonc.2020.08.002

Ejemplares similares

Excellent Outcomes of Patients of Middle Eastern Ethnic Origin with Autologous Haemopoietic Stem Cell Transplantation and COVID-19: Does a Dampened Immune System Protect Against Severe COVID-19?
por: Tailor, Imran K, et al.
Publicado: (2020)

Outcomes of Patients of Eastern Mediterranean Region with Lymphoma and COVID-19.Does Recent Chemo Immunotherapy Have a Role on Severity?
por: Tailor, Imran K, et al.
Publicado: (2020)

An Intriguing Case of Eosinophilia with FIP1L1/PDGFRA Rearrangement Who Presented as Thrombotic Thrombocytopenic Purpura
por: Alshehri, Hassan, et al.
Publicado: (2019)

Thrombotic thrombocytopenic purpura - analysis of clinical features, laboratory characteristics and therapeutic outcome of 24 patients treated at a Tertiary Care Center in Saudi Arabia
por: Iqbal, Shahid, et al.
Publicado: (2016)

Prolonged Survival of a Patient with Chronic Myeloid Leukemia in Accelerated Phase with Recurrent Isolated Central Nervous System Blast Crisis
por: Bin Salman, Ahmed A., et al.
Publicado: (2020)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Systemic Lupus Erythematosus Presenting as Hematoma of the Hand Due to Acquired Inhibitors to Factor VIII: Early and Prolonged Remission Achieved with Upfront Rituximab
por: Zaidi, Abdul Rehman Z, et al.
Publicado: (2019)

Report of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection in Four Patients with Hematological Malignancies Treated at King Fahad Medical City, Riyadh, Saudi Arabia
por: Motabi, Ibraheem H, et al.
Publicado: (2016)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
por: Liberati, Anna Marina, et al.
Publicado: (2013)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Lenalidomide Promotes Thrombosis Formation, but Does Not Affect Platelet Activation in Multiple Myeloma
por: Li, Panpan, et al.
Publicado: (2023)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrian, et al.
Publicado: (2011)

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
por: de Arriba de la Fuente, Felipe, et al.
Publicado: (2022)

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide
por: Du, Li, et al.
Publicado: (2022)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
por: Hitz, F., et al.
Publicado: (2019)

Can Lenalidomide Protect against Severe COVID-19 Symptoms in Multiple Myeloma Patients? A Case Series and Review of the Literature
por: Al Sbihi, Ali, et al.
Publicado: (2022)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

Activation of Coagulation by Lenalidomide-Based Regimens for the Treatment of Multiple Myeloma
por: Isozumi, Yu, et al.
Publicado: (2013)

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
por: Vu, T, et al.
Publicado: (2015)

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma
por: Krönke, Jan, et al.
Publicado: (2017)

Extrapyramidal Symptoms with Administration of Lenalidomide Maintenance Therapy for Multiple Myeloma
por: Sagar, FNU, et al.
Publicado: (2018)

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
por: Moreau, Philippe, et al.
Publicado: (2019)

Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma
por: Gao, Tiantao, et al.
Publicado: (2022)

Cost-Effectiveness of Post-Autotransplant Lenalidomide in Persons with Multiple Myeloma
por: Marchetti, Monia, et al.
Publicado: (2021)

AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2023)

Lenalidomide-Induced Diffuse Alveolar Hemorrhage in Patient With Multiple Myeloma
por: Qanash, Sultan, et al.
Publicado: (2023)

Lenalidomide-Associated ITP
por: Herold, Christina I., et al.
Publicado: (2011)

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
por: Franssen, Laurens E., et al.
Publicado: (2018)

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
por: Minarik, Jiri, et al.
Publicado: (2021)

Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma
por: Schwamborn, Katharina, et al.
Publicado: (2011)

Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
por: Martiniani, Roberta, et al.
Publicado: (2012)

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
por: Richardson, Paul, et al.
Publicado: (2010)

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Siegel, D S, et al.
Publicado: (2014)

Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma
por: Maïga, S, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jhsec3kej6oboj3urddvhoh84l